ALDA Pharmaceuticals Corp.
OTC Bulletin Board : APCSF

ALDA Pharmaceuticals Corp.

May 05, 2009 14:19 ET

ALDA Products Popular at O.D.A. Meeting in Toronto

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 5, 2009) - Representatives of ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") attended the 142nd Annual Spring Meeting ("ASM") of the Ontario Dental Association ("ODA") on April 30 and May 1, 2009. This meeting is the largest dental conference held in Canada and took place at the Metro Toronto Convention Centre. Joining over 275 other exhibitors at the ASM, ALDA presented its new product line to over 10,000 dentists and 25,000 dental staff.

The products on display included:

- T36® Disinfectant

- T36® Disinfectant Wipes

- T36® Antiseptic Hand Sanitizer Gel

- T36® Antiseptic Hand Sanitizer Wipes

- T36® Disinfectant Cleaner CONCENTRATE

All of the products attracted significant interest and a large number of samples were provided to the attendees. The safety and efficacy of T36® Disinfectant was of particular interest as was the ability of T36® Antiseptic Hand Sanitizer to kill Norwalk-like viruses and to have a residual anti-microbial effect, unlike typical alcohol-based hand sanitizers. As a result, T36® Antiseptic Hand Sanitizer Gel and canisters holding 160 T36® Antiseptic Hand Sanitizer Wipes were very popular. With the addition of T36® Disinfectant Cleaner CONCENTRATE to the product line, the attendees recognized that ALDA's products can satisfy all of their infection control needs.

Dr. Terrance Owen, President & CEO, states, "It was very gratifying to see such a positive response to our products. Certainly this was enhanced by the concern over H1N1, the so-called "swine flu". People were very surprised when, as a demonstration of the safety of our products, we sprayed T36® Disinfectant directly onto our hands. Everyone who tried T36® Antiseptic Hand Sanitizer told us that they think it is superior to other comparable products and, when they learned about the greater efficacy and residual effect, were even more interested. We will now be working towards capitalizing on the enthusiasm generated from this conference and commencing our marketing program as soon as possible."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President & CEO

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Contact Information